Who should benefit from the use of alpha-glucosidase inhibitors?

Current Diabetes Reports

Volumn 7, Issue 5, 2007, Pages 333-339

  Godbout, Ariane ^b   Chiasson, Jean Louis ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; AMYLASE; BIGUANIDE DERIVATIVE; CARBOHYDRATE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; ISOPHANE INSULIN; METFORMIN; MIGLITOL; PLACEBO; SULFONYLUREA; VOGLIBOSE;

ADD ON THERAPY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIARRHEA; DIET RESTRICTION; DIET THERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG USE; ENZYME INHIBITION; EXERCISE; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; POSTPRANDIAL STATE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT FAILURE; WEIGHT GAIN;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 36749059401     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0055-x     Document Type: Review

References (43)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:854-865.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group [no authors listed]. Lancet 1998, 352:837-853.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. DCCT Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
4. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
5. Woerle HJ, Neumann C, Zschau S, et al.: Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007, 77:280-285.
6. Bischoff H: Pharmacology of alpha-glucosidase inhibitors. In Drugs in Development, AIpha-Glucosidase Inhibition: Potential Use in Diabetes. Edited by Vasselli JR, Maggio CA, Scriabine A. Branford, Connecticut: Neva Press; 1993:3-13.
7. Seifarth C, Bergmann J, Hoist JJ, et al.: Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabetic Med 1998, 15:485-491.
8. •• van de Laar FA, Lucassen PL, Akkermans RP, et al.: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005, 28:154-163.
9. Josse RG, Chiasson JL, Ryan EA, et al.: Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003, 59:37-42.
10. Johnston PS, Lebovitz HE, Coniff RF, et al.: Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998, 83:1515-1522.
11. Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994, 17:561-566.
12. Chiasson JL, Naditch L: The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001, 24:989-994.
13. Chiasson JL: Alpha-glucosidase inhibitors. In Excerpt from Clinical Diabetes Translating Research into Practice. Edited by Fonseca VA. Toronto: Elsevier Canada; 2007:321-330.
14. Lopez J, Aguilar C, Velasco ML, et al.: Acarbose versus bedtime NPH insulin in the treatment of secondary failures to sulfonylureas metformin therapy in NIDDM. Diabetes 1997, 46(suppl 1):94A 1997.
15. Chiasson JL, Josse RG, Hunt JA, et al.: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994, 121:928-935.
16. Standl E, Baumgartl HJ, Fuchtenbusch M, Stemplinger J: Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab 1999, 1:215-220.
17. Hara T, Nakamura J, Koh N, et al.: An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996, 19:642-647.
18. Coniff RF, Shapiro JA, Seaton TB, et al.: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995, 18:928-932.
19. Gùvener N, Gedik O: Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999, 36:93-97.
20. Soonthornpun S, Rattarasarn C, Thamprasit A, Leetanaporn K: Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial. J Med Assoc Thai 1998, 81:195-200.
21. Edelstein SL, Knowler WC, Bain RP, et al.: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997, 46:701-710.
22. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
23. Report of the expert committee on the diagnosis and classification of diabetes mellitus [no authors listed]. Diabetes Care 1997, 20:1183-1197.
24. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part I: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
25. Yang W, Lixiang L, Jinwu Q, et al.: The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 2001, 17:131-136.
26. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
27. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
28. Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
29. Qiao Q, Tuomilehto J, Borch-Johnsen K: Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003, 46(suppl 1):M17-M21.
30. Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
31. Shiraiwa T, Kaneto H, Miyatsuka T, et al.: Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005, 28:2806-2807.
32. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
33. Balkau B, Shipley M, Jarrett RJ, et al.: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998, 21:360-367.
34. Eschwege E, Richard JL, Thibult N, et al.: Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metah Res Suppl 1985, 15:41-46.
35. Hu FB, Stampfer MJ, Haffner SM, et al.: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
36. Bonora E: Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pratt Suppl 2002, 129:5-11.
37. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 2003, 290:486-494.
38. Hanefeld M, Chiasson JL, Koehler C, et al.: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35:1073-1078.
39. Hanefeld M, Cagatay M, Petrowitsch T, et al.: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
40. Inoue I, Shinoda Y, Nakano T, et al.: Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 2006, 55:946-952
41. Ceriello A, Taboga C, Tonutti L, et al.: Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996, 39:469-473.
42. Wascher TC, Schmoelzer I, Wiegratz A, et al.: Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005, 35:551-557.
43. Gentile S, Turco S, Guarino G, et al.: Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab 2001, 3:33-40.